Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing transformative treatments for patients with severe diseases. Its lead therapeutic candidate, Trappsol® Cyclo™, a proprietary hydroxypropyl beta cyclodextrin formulation, has shown promise in managing cholesterol transport. By mimicking the NPC1 protein, Trappsol® Cyclo™ helps move accumulated cholesterol from cellular lysosomes for processing and excretion. The drug is being evaluated in clinical trials as a potential treatment for Niemann-Pick Disease Type C1 (NPC), a rare genetic disorder, and Alzheimer’s disease, a progressive neurological condition.